Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Bone Biologics (BBLG) Income from Continuing Operations (2016 - 2025)

Bone Biologics has reported Income from Continuing Operations over the past 2 years, most recently at 2769609.0 for Q4 2017.

  • Quarterly Income from Continuing Operations rose 41.05% to 2769609.0 in Q4 2017 from the year-ago period, while the trailing twelve-month figure was 7051573.0 through Dec 2017, up 72.75% year-over-year, with the annual reading at 3112958.0 for FY2025, 25.23% up from the prior year.
  • Income from Continuing Operations was 2769609.0 for Q4 2017 at Bone Biologics, down from 2375739.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 1016301.0 in Q2 2017 and troughed at 12263789.0 in Q1 2016.